Seoulin Bioscience Co.,Ltd. announced that it has received KRW 30 billion in funding from Shinhan Investment Corp., Investment Arm, Hanyang Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, Mirae Asset Capital Co,Ltd., Investment Arm, Cornerstone Investment Partners Co., Ltd., and other investors
November 24, 2021
Share
On November 24, 2021, Seoulin Bioscience Co.,Ltd. closed the transaction.
Seoulin Bioscience Co., Ltd is a Korea-based company engaged in the developing and manufacturing of basic equipment for bio research. The Company mainly engages in research and development of reagents, such as deoxyribonucleic acid (DNA) chips, which are used for gene therapy, clinical diagnosis, organs transplantation and biopsy; stem cells, which are used for treatment of incurable diseases, Alzheimer disease and others, and next-generation biotechnology drugs. The company supplies its products under the brand name MyLab. It also imports bio research equipment from Thermo Fisher, Affymetrix, Sarstedt and others, and markets in the domestic market. In addition, the Company engages in the real estate rental business.
Seoulin Bioscience Co.,Ltd. announced that it has received KRW 30 billion in funding from Shinhan Investment Corp., Investment Arm, Hanyang Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, Mirae Asset Capital Co,Ltd., Investment Arm, Cornerstone Investment Partners Co., Ltd., and other investors
SEOULIN BIOSCIENCE CO.,LTD. 
